Natco Pharma Ltd.

Natco Pharma is currently trading at Rs. 1014.30, up by 5.45 points or 0.54% from its previous closing of Rs. 1008.85 on the BSE.

The scrip opened at Rs. 1001.20 and has touched a high and low of Rs. 1016.65 and Rs. 992.00 respectively. So far 21312 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1188.95 on 24-May-2021 and a 52 week low of Rs. 732.00 on 09-Sep-2020.

Last one week high and low of the scrip stood at Rs. 1036.00 and Rs. 992.00 respectively. The current market cap of the company is Rs. 18423.41 crore.

The promoters holding in the company stood at 48.87%, while Institutions and Non-Institutions held 29.94% and 21.19% respectively.

Natco Pharma has transferred the Lenalidomide Capsules ANDA (2.5mg, 5mg, 10mg, 15mg, 20mg and 25mg strengths) to Arrow International as per an earlier agreement between the parties. This transfer of the ANDA to Arrow does not materially change any of the terms of the agreement between the parties.

Arrow International (an affiliate of Teva Pharmaceutical Industries) is the marketing partner of NATCO for this product in the US market. The ANDA was approved by USFDA in May 2021 with final approval in the 5mg, 10mg, 15mg, and 25mg strengths, and tentative approval in the 2.5mg and 20mg strengths.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.